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Although TGF-b is inhibitory to many cancer cells in vitro (Laiho
et al, 1990; Pietenpol et al, 1990), most tumours that express large
quantities of TGF-b exhibit an aggressive phenotype (Barrack,
1997). On the other hand, tumours that have a reduced production
of TGF-b show an attenuated growth pattern in vivo (Fakhrai et al,
1996). This difference of in vitro and in vivo responses of tumour
cells to TGF-b is well known. What remains unclear is the impact
by the host immune system on in vivo tumour growth due to an
overproduction of TGF-b. The present report described the role of
TGF-b production in host immune surveillance program against
tumour growth.
Among the Dunning’s rat prostate tumours, MATLyLu is the
most aggressive line (Issacs et al, 1981; 1986). The MATLyLu
system has been well characterized and is considered to be a good
model for the late-stage, aggressive form of human prostate cancer
(Smolev et al, 1977). These cells are androgen-independent and
are highly invasive and metastatic. MATLyLu cells are known to
be either non-immunogenic, or at best, weakly immunogenic
(Shaw et al, 1987; Vieweg et al, 1994). They also produce a large
amount of TGF-b1 (Steiner and Barrack, 1992; Barrack, 1997).
Since TGF-b is a potent immunosuppressant (Letterio and
Roberts, 1998), the lack of immunogenicity in these cells may be
due, at least in part, to the large amount of endogenous production
of TGF-b. MATLyLu cells are sensitive to TGF-b (Morton and
Barrack, 1995). They demonstrate the typical paradoxical in vitro
verses in vivo growth pattern in response to TGF-b1 (Barrack,
1997). Under culture conditions, TGF-b inhibits proliferation of
MATLyLu cells. However, in animals, TGF-b1 enhances the
tumorigenicity. This enhanced tumorigenicity may be the result of
tumour–host interaction through a multitude of pathways.
In the present study, we demonstrate that the immunosuppres-
sive effect of TGF-b plays a major role in MATLyLu tumori-
genicity. The present results allow us to conclude that MATLyLu
cells can be immunogenic when the endogenous production of
TGF-b has been suppressed.
MATERIALS AND METHODS
MATLyLu cells and culture conditions
MATLyLu cells were kindly provided by Dr John Isaacs of Johns
Hopkins University at passage 53. Cells were routinely maintained
in RPMI 1640 medium (Gibco Life Technologies, Gaithersburg,
MD, USA) with 10% FBS (Summit, Ft. Collins, CO, USA),
penicillin (100 units ml–1), streptomycin (100 mg ml–1) (Gibco),
and 250 nM dexamethasone. All cells were cultured in a humidi-
fied atmosphere of 95% air and 5% CO2 at 37°C. Cells under
selective pressure were cultured as above with the addition of
G418-sulphate (1000 mg ml–1). Transfection of expression
constructs to MATLyLu cells was performed at passage 71 and
cells were used for the present study between passages 80–90.
Construction of the TGF-b1 antisense expression
vector
The pTARGET plasmid (Promega, Madison, WI, USA) is a
mammalian expression vector containing the human
cytomegalovirus immediate–early promoter region to allow
constitutive expression of the cloned vector in host cells. This
plasmid also contains a neomycin resistance gene, which was used
for selection by G418-sulphate. The vector consisted of base pairs
(bp) 433–1461 of the rat TGF-b1 cDNA in the reverse orientation
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plasmid. Resulting constructs were digested with restriction
enzymes and sequenced to confirm correct orientation, and desig-
nated as the TGF-b1 antisense construct. A construct with the
empty vector (pTARGET plasmid alone) was prepared in the same
manner, and designated as the control construct.
Transfection and cloning
MATLyLu cells were transfected with the TGF-b1 antisense and
control constructs with the LipofectamineTM transfection system
(Gibco) according to the manufacturer’s recommended proce-
dure. Briefly, cells were suspended in Opti-mem transfection
media and were treated with a mixture of LipofectamineTM and
the above constructs (TGF-b1 antisense or control) for 18 h.
Following transfection, cells were cultured with the maintenance
medium and selected with G418-sulphate. Three days later, these
cultures were transfected again and this procedure was repeated
for a total of five times. Cloning was performed by limiting dilu-
tion into 96-well plates (Costar, Cambridge, MA, USA). Seven
days after the initial plating, cells in a single colony were
harvested and transferred into 24-well plates. At confluency,
these cells were subsequently transferred into 25 cm2 flasks and
further expanded. Prior to injection of these cells into animals, the
following tests were conducted.
Verification of cloned MATLyLu cells by PCR
Confluent cultures were trypsinized and DNA was extracted via
the Qiagen DNA preparation kit (Qiagen Inc, Chatsworth, CA,
USA). DNA contents were measured by UV absorbence. An
aliquot of 1.0 mg of genomic DNA was introduced into each PCR
reaction vessel along with primers specific for a sequence within
the vector. DNA sequences for the respective primers are listed
below.
5¢ primer-5¢-GCACC AAAAT CAACG GGACT-3¢ (bp 619–
638)
3¢ primer-5¢-GAGAG AAAGG CAAAG TGGAT GTC-3¢ (bp
995–1017)
An aliquot of 10 ml reaction buffer, containing 0.5 mg of Taq poly-
merase (ISC Bioexpress, Kaysville, UT, USA), 25 mM of dNTPS,
3 mM of MgCl2, was added into each PCR reaction vessel and
incubated for 35 cycles in a thermocycler (MJ Research,
Watertown, MA, USA). Each cycle consisted of 95°C for 2 min,
55°C for 1 min and 72°C for 1.5 min. The PCR products were
subjected to electrophoresis on a 0.8% agarose gel, stained with
ethidium bromide, and were visualized under a UV lamp. The
expected size (399 bp) of the PCR product was determined
according to the DNA size reference, which was placed in the first
and last lanes in the agarose gel for electrophoresis. Portions of the
PCR products were also subjected to restriction digest and, then, to
agarose electrophoresis to confirm the expected sequence.
In vitro 3H-thymidine incorporation
3H-thymidine incorporation was carried out to assess proliferative
potential of each clone. Cells were seeded at 10 000 cells per well
in 96-well plates and cultured in serum-free media. Twenty-four
hours later, 1.0 mCi of 3H-thymidine (specific activity, 20–
30 Ci mmol–1, Amersham, Piscataway, NJ, USA) was added to
each well. Cells were incubated for an additional 2 h and were
subjected to two freeze–thaw cycles to detach cells from the wells.
Suspended cells were transferred to a glass filter (Packard
Instrument Company, Meriden, CT, USA) and were lysed with
distilled water. Plates were allowed to dry for 2 h and an aliquot of
50 ml scintillation fluid was added. The amount of radioactivity
was measured in a Scintillation Top Count Plate Reader (Packard
Instrument Company). Results were expressed as counts per
minute per well.
Preparation of tumour and cell lysates for TGF-b1
determination
Levels of TGF-b1 in cell lysates and tumour tissues were deter-
mined by enzyme-linked immunosorbant assay (ELISA). Tumour
tissues, weighing from 200–600 mg, were frozen with liquid
nitrogen and ground to a powder. The solubilizing solution was
added to each sample at a rate of 3 ml (phosphate buffer, 100 mg
leupeptin) per 100 mg of tissue. Cell lysates were prepared by
addition of 3 ml of the solubilizing solution to cell pellets (10 ´ 106
cells). These samples were subjected to constant shaking at room
temperature for 4 h and centrifuged for 15 min at 1500 g. The
clear supernatants were used for TGF-b1 determination. Briefly,
an aliquot of 100 ml of the supernatant was activated with 100 ml
2.5 N HCl and 10 M Urea for 10 min. The activation step was
necessary, as the amount of TGF-b1 in untreated samples was
always negligible. Samples were neutralized with 100 ml of 2.7 M
NaOH and 1.0 M HEPES prior to assay for TGF-b1. Samples
were diluted 1:30 in calibrator diluent and subjected to ELISA for
TGF-b1 (R&D, Minneapolis, MN, USA) according to the manu-
facturer’s suggested procedure. Results were reported as pg TGF-
b1 per 50 mg of tumour tissue or per 2 ´ 104 cells.
Experimental animals
Copenhagen male rats (syngeneic hosts), Lewis male rats (allo-
geneic hosts), and athymic nude rats (immunodeficient hosts)
were purchased from Harlan Industry (Indianapolis, IN, USA) at
60 days of age. Animals were kept in a temperature controlled
room (23 ± 2°C) with tap water and normal rat chow provided ad
lib. Experiments started at least 1 week after animals arrived at the
facility. They were anaesthetized under methoxyflurane vapour
(Schering-Plough, Union, NJ, USA). MATLyLu cells (2 ´ 105
cells for syngeneic hosts and immunodeficient hosts, I ´ 106 cells
for allogeneic hosts) were suspended in 0.2 ml of serum-free
culture medium and injected subcutaneously with a 25-guage
needle into the left flank near the hind leg, while the animals were
under anaesthesia. All procedures were approved by the
Institutional Animal Care and Use Committee.
Tumour measurement and tumour histology
Seven days following injection, rats were palpated twice weekly in
order to monitor tumour development and tumour progression.
When a tumour was palpated, the interval between tumour cell
injection and tumour development was considered as the tumour-
latent period. Tumour size was measured with calipers and tumour
volume was determined by applying the formula (0.5236 (W + L)
(W ´ L))/2, where W represents the width and L is the length
(Janik et al, 1975). Animals were euthanized at 21–23 days by
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decapitation while under anaesthesia with methoxyflurane vapour.
Tumours were dissected and weighed. Tumours were cut into
small pieces and were snap-frozen in liquid nitrogen for PCR
analysis. A portion of each tumour was fixed in 10% neutral
formalin. Tissues for histologic studies were embedded in paraffin,
cut at 6.0 mm thick, and stained with haematoxylin and eosin.
Photomicrographs of representative sections of the tumour tissues
were taken with a camera mounted on a microscope (Olympus
Model BH-2) as a hard-copy record.
Statistical analysis
All numerical data were expressed as mean ± standard error of the
mean (SEM). All in vitro experiments were repeated at least three
times. Data were analysed using the analysis of variance test and
Duncan’s new multiple range test (Bender et al, 1982; Steele and
Torrie, 1960). The Chi-square test was used to determine differ-
ences in tumour incidences in animals. A linear correlation was
conducted to test the degree of association between the value of
3H-thymidine incorporation and the level of TGF-b1 production
for different clones. A correlation coefficient (r) was calculated
based on the analysis. A P value of less than 0.05 was considered
as statistically significant (Steele and Torrie, 1960; Bender et al,
1982).
RESULTS
Verification of TGF-b1 antisense transfection in
MATLyLu cells
A TGF-b1 antisense vector was created by inserting the full-length
rat TGF-b1 cDNA into the multiple cloning site of the pTarget
vector in the reverse orientation. MATLyLu cells were transfected
with this construct, selected with G418-sulphate, and re-trans-
fected in order to assure that high copy numbers of the vector were
present. The repeated transfection appeared necessary, as
MATLyLu cells produce high levels of TGF-b1. Early attempts
using a single transfection episode were unsuccessful in reducing
TGF-b1 production in transfected cells. It is likely that a great
measure of antisense RNA must be present in the cytoplasm in
order to suppress TGF-b1 production. Following serial dilution,
clones were chosen. DNA from these cloned cells was isolated for
PCR analysis. The positive detection of the expected 399 bp PCR
product derived from transfected cell lines confirmed the presence
of the transfected construct. Levels of TGF-b1 in cell lysates, as
determined by ELISA, were significantly lower in clones trans-
fected with the TGF-b1 antisense vector than in those of wild type
MATLyLu cells and cells transfected with the control construct.
The clone with the lowest level of TGF-b1 (clone 18) was chosen
for further studies (Table 1 and Figure 1).
3H-Thymidine incorporation assay
3H-thymidine incorporation in these cells was measured to deter-
mine proliferation rates of the various positive clones. There was a
negative correlation between values of 3H-thymidine incorporation
Table 1 Levels of TGF-b1 in cell lysates and 3H-thymidine incorporation rates of wild type MATLyLu cells,
cells transfected with the control construct and cells transfected with the TGF-b1 antisense construct
TGF-b1 3H-Thymidine Incorporation
Cell type (pg per 2 ´ 104 cells) (cpm per 1 ´ 104 cells per well)
Wild type MATLyLu cells 70.3 ± 7.7 6804 ± 434
Cells with control vector 67.0 ± 11.8 10 774 ± 700
Cells with antisense vector (Clone 18) 9.9 ± 1.2a 30 348 ± 2 866a
All values are expressed as mean ± standard error of the mean. aThe value is significantly different from
the other values in the same column (P < 0.05)
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Figure 1 The proliferation rates of wild type cells (WT), cells transfected
with the control vector (CV), and different antisense clones in vitro (A), 3H-
thymidine incorporation, and levels of TGF-b1 production (B) ELISA. Clone
18 (c18) was selected because it was the fastest growing and had the lowest
level of TGF-b1 production of all of the antisense clones that were screened522 E Matthews et al
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and TGF-b1 levels in different clones (r = 0.769, n = 7, P < 0.05).
Clone 18 has the highest level of 3H-thymidine incorporation,
which was 3- to 5-fold higher than the proliferation rates for the
wild type cells and cells transfected with the control construct
(Table 1 and Figure 1). Therefore, this clone was chosen for further
investigation.
Tumour-latent period, incidence, and progression of
MATLyLu cells in animals
The tumour-latent period is defined as the interval between tumour
cell inoculation and detection of palpable tumour nodules. Table 2
shows, in male Copenhagen rats (syngeneic hosts), 100% of
tumour development from wild type MATLyLu cells (15/15) and
cells transfected with the control construct (15/15); but only 43%
in animals injected with clone 18 cells (9/21). The average latent
period for tumour development was 12 ± 0.54 days (mean±SEM)
for the wild type MATLyLu cells and cells transfected with the
control construct, for clone 18 cells, the average latent period was
25.2 ± 3.4 days (P < 0.05). Furthermore, tumours derived from
clone 18 cells had an average weight (2.5 ± 1.3 g at day 41) signif-
icantly less than those derived from wild type MATLyLu cells
(15.5 ± 4.3 g) and cells transfected with the control construct
(12.6  ± 3.7 g) at day 21 (Figure 2A).
The experiment was repeated in male nude rats (immunodefi-
cient hosts) and in Lewis rats (allogeneic hosts). As indicated in
Table 2, tumour incidence of clone 18 cells grown in nude rats was
90% (9/10), which was not significantly different from those of
wild type MATLyLu cells (10/10) or of cells transfected with the
control construct (10/10). The latent period (8–11 days) of tumour
Table 2 Tumour incidence of MATLyLu cells inoculated subcutaneously into syngeneic, allogeneic, and immunodeficient hosts
Trial I Trial II Trial III Overall
Syngeneic hosts:
Wild type MATLyLu cells 5/5 (100%) 5/5 (100%) 5/5 (100%) 15/15 (100%)
TGF-b1 antisense transfected cells 3/5 (60%) 4/11 (36%)a 2/5 (40%) 9/21 (43%)a
Control construct transfected cells 5/5 (100%) 5/5 (100%) 5/5 (100%) 15/15 (100%)
Allogeneic hosts:
Wild type MATLyLu cells 4/4 (100%) – – 4/4 (100%)
TGF-b1 antisense transfected cells 0/5 (0%)a – – 0/5 (0%)a
Control construct transfected cells 4/5 (80%) – – 4/5 (80%)
Immunodeficient hosts:
Wild type MATLyLu cells 5/5 (100%) 5/5 (100%) – 10/10 (100%)
TGF-b1 antisense transfected cells 5/5 (100%) 4/5 (80%) – 9/10 (90%)
Control construct transfected cells 5/5 (100%) 5/5 (100%) – 10/10 (100%)
All values are expressed as mean ± standard error of the mean. a The value is significantly different (P < 0.05) from other values in the same
group by the c2-square test. In syngeneic hosts and immunodeficient hosts, a total of 2 ´ 105 cells were injected s.c. In allogeneic hosts, a total
of 1 ´ 106 cells were injected s.c. Three separate trials were conducted for syngeneic hosts. One trial was conducted for the allogeneic hosts
and two trials were conducted for immunodeficient hosts.
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Figure 2 Growth curves of tumours in Copenhagen rats (A) (syngeneic hosts) and in nude rats (B) (immunodeficient hosts). Tumour volumes were calculated
according to the formula described in the text (Janik et al, 1975). Tumour volume in each group was calculated as mean ± SEM of all tumours. Tumours
developed from the wild type MATLyLu cells (open squares) and cells transfected with the control vector (open triangles) were significantly bigger with a shorter
latent period than those developed from the antisense vectors (open circles). Note that the scales in (A) and (B) are different, suggesting that tumours grow
faster in immunodeficient hosts during the same interval. The vertical bars denote standard error of the mean.emergence was not significantly different, in contrast to the extended
latent period observed in the syngeneic hosts. Furthermore, the
tumour mass of clone 18 cells was significantly smaller (P < 0.05)
from that of wild type cells or cells transfected with the control
construct (Figure 2B). This observation suggests that for clone 18
cells, the host–immune responses as well as non-immune responses
contributed to the reduced tumour growth in Copenhagen rats.
Tumour incidence in Lewis rats (allogeneic hosts) was also studied in
a small series. Results indicated that, in Lewis rats, there was a 100%
tumour development for wild-type MATLyLu cells (4/4), 80% for
cells transfected with the control construct (4/5) and 0% in animals
injected with clone 18 cells (0/5) (Table 2).
Characterization of MATLyLu tumours
Histologic features of tumours were similar to those reported in the
literature (Isaacs et al, 1981, 1986). They contained highly undif-
ferentiated tumour cells, resembling those of Gleason 5 anaplastic
prostate adenocarcinoma. Mitotic figures were frequently seen.
When tumour size was greater than 1.0 cm in diameter, central
necrosis was evident. The periphery of the tumour was always
surrounded by fibrous tissue derived from the host. In the present
study, since tumours were harvested at a relatively early stage, the
incidence of metastasis was not frequent. There were no apparent
differences in morphologic features of tumours harvested from
different treatment groups.
Results of PCR analysis for the presence of the expression
vector indicated that clone 18 cells contained the expected 399 bp
PCR product. Levels of TGF-b1 in the tumour lysates were deter-
mined by ELISA. As shown in Figure 3, in syngeneic as well as in
athymic rats, tumours derived from the three different cell types
showed comparable levels of TGF-b1. These results suggest that
tumours derived from these cells all contain relatively high levels
of TGF-b1 regardless of whether or not the original inoculum
produced a low level of the growth factor.
DISCUSSION
Results of the present study have demonstrated that MATLyLu
cells, when the production of TGF-b1 is reduced, proliferate more
rapidly under in vitro conditions but are less tumorigenic under in
vivo conditions. The difference in growth behaviour of tumour
cells under these two conditions is likely due to tumour–host inter-
actions. It is widely accepted that wild type MATLyLu cells are
non-immunogenic or, at best, weakly immunogenic (Shaw et al,
1987; Vieweg et al, 1994). Many experimental immunotherapy
protocols have failed to cure the MATLyLu tumour (Vieweg et al,
1994). Results of the present study have demonstrated that the
wild type MATLyLu cells produce high levels of TGF-b1 and
are immuno-suppressive (Steiner and Barrack, 1992; Barrack,
1997). By simply reducing the production of the endogenous
TGF-b1, MATLyLu cells showed a reduced tumour incidence in
immune-competent hosts but not in immune-deficient hosts.
TGF-b is a potent immunosuppressant (Karpus et al, 1991;
Leterio and Roberts, 1998). The notion that many tumour cells
produce large quantities of TGF-b has been acknowledged
(Gomella et al, 1992). Therefore, it is reasonable to propose that
many tumour cells are immunosuppressive and that they are able
to escape the host immune surveillance system. Basically, the
present study observed the effect of TGF-b1 production by the
tumour cells on three tumorigenic events: the incidence of tumour
formation, the latent period, and the progression of established
tumours. The first two events are clearly T-cell mediated, as there
are significant differences in tumour incidence and the latent
period between the syngeneic hosts and immune-deficient hosts.
The third event may involve factors other than T-cell mediated
immune system, as the impact of a reduced production of TGF-b1
on tumour progression is apparent in both syngeneic hosts and in
immune-deficient hosts. These issues will be addressed below.
Xenograft growth of tumour cells in athymic hosts offers an
opportunity to assess the behavior of tumour development under
immune-compromised conditions. These animals are deficient in
T cells but their natural killer (NK) cells remain functional. If
tumours fail to develop in immune-competent hosts but grow in
immunodeficient hosts, it is likely that the observed difference in
tumour incidence is at least in past due to a functional T-cell
immune system. In the present study, this is the case for tumour
incidence and the latent period for tumour development, as the
incidence has been significantly reduced and the latent period has
been significant delayed in syngeneic hosts when compared with
those events in the nude rats. Therefore, a reduction in TGF-b1
production in the tumour cells results in an escape from the T-cell
mediated immunosuppression.
It is clear that the tumour–host interaction involves factors other
than the T-cell immune system. These non-T cell factor may also
play an important role in tumourigenicity. Nude rats, although
lacking T cells, retain some immune function, as they still have
NK cells, which may perform some tumour-suppressive functions.
It is likely that the observed retardation in tumour growth in nude
rats receiving clone 18 cells may result from the activation of NK
TGF-b1 and immunogenicity in prostate cancer cells 523
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Figure 3 Levels of TGF-b1 in tumours derived from Copenhagen rats (A)
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expressed as mean ± SEM for at least five tumours in each group. TGF-b1
was determined by ELISA as described in the text. The vertical bars denote
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cells due to the low levels of TGF-b1 produced by these cells.
Differences in tumour growth may not completely attributed to the
host immune system. It is apparent, from the present result, that
the host immune system is one of many host factors that can be
influenced by the production of TGF-b1 by tumour cells (Karpus
et al, 1991; Leterio and Roberts, 1998).
In addition to immune suppressive function, TGF-b1 produc-
tion by tumour cells can be responsible for many non-immune host
factors, which cannot be ruled out at this stage. These are angio-
genesis, stromal–epithelial interaction, expression of adhesion
molecules, and production of extracellular matrix proteins
(Battegay et al, 1990; Welch et al, 1990; Yang and Moses, 1990;
Karpus et al, 1991; Barrack, 1997). These factors can promote
tumour progression. In an environment of reduced TGF-b1
production, the in vivo tumour growth will be hampered. Results
from studies with immunodeficient hosts indicate that tumours
derived from the wild type MATLyLu cells and cells transfected
with the control construct grow faster than those derived from the
TGF-b1 antisense transfected cells do. These results indicate that
the high levels of TGF-b1 produced by the wild type MATLyLu
cells and by cells transfected with the control construct are able to
stimulate a greater degree of tumour growth than that of the TGF-
b1 antisense transfected MATLyLu cells. These factors may also
contribute toward MATLyLu tumour growth.
An interesting finding in this study is that MATLyLu cells,
when their TGF-b1 production is reduced, exhibit a low tumour
incidence and a prolonged tumour-latent period in syngeneic
hosts. When these tumour lysates were subjected to ELISA,
however, the average level of TGF-b1 was not significantly
different from that of the wild type tumours. Although results of
PCR analysis indicate the presence of the antisense expression
construct, the possibility could not be ruled out that some of the
clone 18 cells might have lost their antisense constructs. We also
acknowledge the possibility that a small fraction of the low TGF-
b1-producing cells were never successfully transfected with the
antisense vector. In either case, the consequence is the emergence
of wild type cells in these tumours. The interesting aspect of this
observation is that growth of these tumours appeared to be
suppressed. A question has been raised of whether or not these
TGF-b1-producing clone 18 cells would grow tumours as large as
those derived from wild type MATLyLu cells, if they are left in
Copenhagen rats for longer periods. We speculate that they would
not grow as aggressively as the wild type tumours. This is because,
when the low TGF-b1-producing clone 18 cells were injected into
syngeneic hosts, they have been immunized and are capable of
rejecting wild type tumour cells at least for a few months. This line
of rationale is based on the report by Fakhrai et al (1996). These
authors used the same method to transfect TGF-b2 antisense
vectors into rat glioma cells and observed a similar reduction in
tumourigenicity in syngeneic hosts. Subsequently, they re-chal-
lenged the wild type glioma cells to hosts who had previously
rejected tumours. These re-challenged cells were also rejected,
suggesting that, at that stage, host animals have been immunized
to reject tumour cells even if they produce high levels of TGF-b.
In the present study, the acquisition of immunogenicity in low
TGF-b1 producing MATLyLu cells was further substantiated by a
lack of tumour growth in allogeneic hosts. In a preliminary study,
tumours derived from wild type MATLyLu cells were eventually
rejected by allogeneic hosts (Lewis rats) at 28 days following the
initial tumour-cell inoculation. The growth of MATLyLu tumours
in Lewis rats is a typical allogeneic transplantation rejection,
which is characterized by an acute T-cell mediated reaction
(Sherman and Chattopadhyay, 1993). However, during the first 14
days following inoculation of tumour cells, tumours grew from the
wild type MATLyLu cells and cells transfected with the control
construct, but not for TGF-b1 antisense transfected cells. This
observation suggests that the high TGF-b1-producing tumours are
endowed with a potent immunosuppressive shield, which protects
them from the initial phase of allogeneic rejection.
In conclusion, the present observations have allowed us to
conclude that MATLyLu cells, upon down-regulation of TGF-b1
production, become growth stimulated under in vitro conditions
and growth inhibited under in vivo conditions. The in vivo growth
inhibition is likely due to the presence of tumour–host interaction.
The tumour–host interaction includes the host immune system and
non-immune responses. Therefore, we propose that MATLyLu
cells are actually immunogenic and that this immunogenic prop-
erty has been masked by the endogenous production of a high
level of TGF-b1. The high level of TGF-b1 in MATLyLu cells is a
critical factor that renders these cells non-immunogenic. Reducing
the endogenous production of TGF-b1 restores the immuno-
genicity in these cells. Our future studies will focus on cellular and
humoral mechanisms that mediate such restoration of immuno-
genicity in MATLyLu cells. Understanding this mechanism may
lead to the development of therapeutic programs based on
lowering the level of TGF-b production in tumour cells.
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